Literature DB >> 1432704

Biotin delivery to brain with a covalent conjugate of avidin and a monoclonal antibody to the transferrin receptor.

T Yoshikawa1, W M Pardridge.   

Abstract

The OX26 mouse monoclonal antibody to the rat transferrin receptor undergoes transcytosis through the brain capillary endothelial wall, which makes up the blood-brain barrier (BBB) in vivo, owing to high concentrations of transferrin receptor on the BBB. This property allows the OX26 antibody to serve as a brain drug transport vector. To simplify coupling of therapeutics to the OX26 antibody, the present studies examine the use of the avidin/biotin system to promote coupling of biotin and biotinylated drugs to brain transport vectors. The OX26 antibody was affinity purified from ascites fluid and was covalently coupled via a thioether linkage to avidin, and the conjugate was purified to homogeneity by gel filtration fast protein liquid chromatography. The biotin binding capacity of the avidin-OX26 conjugate was measured, and 2.3 biotin binding sites per avidin-OX26 (1:1) conjugate were detected. Transcytosis through the BBB of [3H]biotin bound to either unconjugated avidin or to the avidin-OX26 conjugate was measured with an internal carotid artery perfusion/capillary depletion technique. [3H]Biotin bound to the avidin-OX26 conjugate was transported through the BBB at rates that equaled the rate of transcytosis of the unconjugated OX26 antibody. The clearance from plasma of [3H]biotin bound to the avidin-OX26 conjugate approximated the rate of clearance of the unconjugated OX26 antibody, and not the rate of clearance of [3H]biotin bound to avidin, which was cleared from plasma at much faster rates.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1432704

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  19 in total

1.  Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor.

Authors:  D Wu; J Yang; W M Pardridge
Journal:  J Clin Invest       Date:  1997-10-01       Impact factor: 14.808

2.  Pharmacologic effects in vivo in brain by vector-mediated peptide drug delivery.

Authors:  U Bickel; T Yoshikawa; E M Landaw; K F Faull; W M Pardridge
Journal:  Proc Natl Acad Sci U S A       Date:  1993-04-01       Impact factor: 11.205

3.  Effects of cellular pharmacology on drug distribution in tissues.

Authors:  R K Rippley; C L Stokes
Journal:  Biophys J       Date:  1995-09       Impact factor: 4.033

4.  Bidirectional apical-basal traffic of the cation-independent mannose-6-phosphate receptor in brain endothelial cells.

Authors:  Piotr Siupka; Maria Ns Hersom; Karin Lykke-Hartmann; Kasper B Johnsen; Louiza B Thomsen; Thomas L Andresen; Torben Moos; N Joan Abbott; Birger Brodin; Morten S Nielsen
Journal:  J Cereb Blood Flow Metab       Date:  2017-03-24       Impact factor: 6.200

Review 5.  Current application of CRISPR/Cas9 gene-editing technique to eradication of HIV/AIDS.

Authors:  Z Huang; A Tomitaka; A Raymond; M Nair
Journal:  Gene Ther       Date:  2017-06-01       Impact factor: 5.250

6.  Targeting of skeletal muscle in vitro using biotinylated immunoliposomes.

Authors:  Anita Schnyder; Stefan Krähenbühl; Michael Török; Jürgen Drewe; Jörg Huwyler
Journal:  Biochem J       Date:  2004-01-01       Impact factor: 3.857

7.  Intravenous siRNA of brain cancer with receptor targeting and avidin-biotin technology.

Authors:  Chun-Fang Xia; Yufeng Zhang; Yun Zhang; Ruben J Boado; William M Pardridge
Journal:  Pharm Res       Date:  2007-10-11       Impact factor: 4.200

8.  Transport of human recombinant brain-derived neurotrophic factor (BDNF) through the rat blood-brain barrier in vivo using vector-mediated peptide drug delivery.

Authors:  W M Pardridge; Y S Kang; J L Buciak
Journal:  Pharm Res       Date:  1994-05       Impact factor: 4.200

9.  Brain delivery of biotin bound to a conjugate of neutral avidin and cationized human albumin.

Authors:  Y S Kang; W M Pardridge
Journal:  Pharm Res       Date:  1994-09       Impact factor: 4.200

10.  Strategies for enhanced drug delivery to the central nervous system.

Authors:  V S N M Dwibhashyam; A N Nagappa
Journal:  Indian J Pharm Sci       Date:  2008 Mar-Apr       Impact factor: 0.975

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.